Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]THK-5351 PET in Alzheimer's Disease and Healthy Subjects
NCT03112096Phase 1Completed
- Sponsor
- The Asan Foundation
- Start
- May 2017
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of 18F-THK5351 in Alzheimer's disease (AD) (2 arms), sponsored by The Asan Foundation. Primary endpoints: Maximum Serum Concentration and Standard Uptake Value Ratio. Started May 2017; status: completed.
02
Drugs
18F-THK5351
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03112096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03112096.